CNS Pharmaceuticals (CNSP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CNSP CNS Pharmaceuticals

Watchlist

0.2162
-0.0014-0.64%

Close May 31 16:00 ET

0.2064
-0.0098-4.53%

Post 17:38 ET

2.56MMarket Cap-76P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21st at 1:40 PM ETHOUSTON, TX / ACCESSWIRE / May 20, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company spe
AccesswireMay 20 08:30 ET
Express News | CNS Pharmaceuticals Q1 EPS $(0.41) Up From $(2.59) YoY
BenzingaMay 16 08:13 ET
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing the most aggressive type of brain cancer with an average survival of
AccesswireMay 16 07:45 ET
CNS Pharmaceuticals | 10-Q: Quarterly report
SEC announcementMay 15 17:06 ET · Announcements
Express News | CNS Pharmaceuticals Inc Files for Mixed Shelf of up to $75 Mln - SEC Filing
ReutersMay 9 17:29 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
BenzingaMay 9 08:06 ET

Comments

Trytosaveabit

May 16 07:19

$CNS Pharmaceuticals(CNSP.US)$ CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.41) per share. This is a 84.17 percent increase over losses of $(2.59) per share from the same period last year.

Trytosaveabit

May 8 15:10

Update

$CNS Pharmaceuticals(CNSP.US)$ On May 6, 2024, the Company received notification from the Nasdaq Hearings Panel (“Panel”) that it has granted an extension until July 15, 2024, to demonstrate compliance with Listing Rules 5550(a)(2) and 5550(b). The Company intends to implement its plan to meet the milestones set forth by the Panel prior to July 15, 2024.